The present invention relates to new polymorphs of LXRß agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXRß agonist, as well as methods of treating cancer including administration of a formulation including an LXRß agonist to a subject in need thereof.